In addition, FDA-approved CDK4/CDK6 inhibitors, including ribociclib, abemaciclib, and palbociclib, as well as other CDK antagonists, are presently in clinical trials as single agents or combined with other drugs for various cancer types. Here, CDK6 is linked to cancer.